BRAF mutation, leading to the constitutive activation of this pathway, is notably involved in the process of oncogenesis of some melanoma, non-small cell lung cancer or colorectal cancer, for which BRAF inhibitors are validated in combination [78,79,80]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.